CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
Topline Capital Partners (WA:CPAP), LP, a significant shareholder in Paysign, Inc. (NASDAQ:PAYS), recently disclosed the sale of a substantial portion of its holdings in the company. Over the course of three transactions, the firm sold a total of 479,105 shares of Paysign common stock, generating proceeds of approximately $1.5 million. The sales occurred between December 27 and December 31, 2024, with share prices ranging from $3.03 to $3.31. The timing is notable as Paysign's stock has experienced a significant 29% decline over the past six months, though analysts maintain a bullish outlook with price targets ranging from $6.00 to $7.25.
Following these transactions, Topline Capital Partners retains ownership of 5,611,128 shares in Paysign. The transactions were reported in a filing with the Securities and Exchange Commission, underscoring Topline's continued role as a major stakeholder in the company. According to InvestingPro analysis, Paysign currently shows signs of being undervalued, with strong financial health metrics and a 28% revenue growth in the last twelve months. Subscribers can access 7 additional ProTips and comprehensive valuation analysis in the Pro Research Report.
In other recent news, Paysign, Inc. has reported a year-over-year revenue growth of 23%, amounting to $15.3 million in its third-quarter earnings call. The company also displayed a rise in adjusted EBITDA by 20.6% to $2.8 million. These recent developments indicate a robust performance, particularly in Paysign's patient affordability business. The firm has also revealed plans for expansion, including a new partnership with a leading pharmaceutical company. Despite facing challenges in the plasma business and ongoing investments, Paysign maintains a positive outlook with expected revenues between $56.5 million and $58.5 million and a net income guidance of $3 million to $3.5 million. Furthermore, the company's patient affordability segment surged by 219% with 66 active programs, and its plasma donor compensation revenue grew by 3.4% to $11.4 million. Lastly, Paysign anticipates year-over-year revenue growth of 20% to 24% and forecasts a net income of $3 million to $3.5 million for the full year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.